Coeliac disease: Between "pizza" and ethics [15]

Gut

Volumn 55, Issue 11, 2006, Pages 1672-

  Elli, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TRANSGLUTAMINASE INHIBITOR; UNCLASSIFIED DRUG; VACCINE;

CELIAC DISEASE; CEREAL; DRUG EFFICACY; FOLLOW UP; GLUTEN FREE DIET; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INTESTINE INJURY; LETTER; MEDICAL ETHICS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; SYMPTOMATOLOGY;

CELIAC DISEASE; GLUTEN; HUMANS; TREATMENT OUTCOME;

EID: 33750346196     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.103903     Document Type: Letter

References (3)

1. Bardella MT, Molteni N, Prampolini L, et al. Need for follow up in coeliac disease. Arch Dis Child 1994;70:211-13.
2. Sollid LM, Khosla C. Future therapeutic options for celiac disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:140-7.
3. Hogberg L, Stenhammar L, Falth-Magnusson K, et al. Anti-endomysium and anti-gliadin antibodies as serological markers for a very late mucosal relapse in a coeliac girl. Acta Paediatr 1997;86:335-6.